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Pancreatic ductal adenocarcinoma is characterized by an extensive 
stromal component that hinders treatment. A new study shows how the 
genetic makeup of pancreatic tumors may influence the physical properties of 
the associated stroma to promote tumor progression. 
 
Pancreatic cancer is a leading cause of cancer deaths, with poor survival 
rates and little improvement in patient outcomes despite considerable effort directed 
at optimizing therapies 1. To improve therapeutic responses and increase survival, 
factors that make pancreatic cancer so deadly and so difficult to treat must be 
identified. In this issue of Nature Medicine, Laklai et al. 2 reveal how mechanical 
properties of the pancreatic cancer microenvironment promote tumor 
aggressiveness. 
 Numerous studies have examined genomic alterations in pancreatic cancer 3, 
revealing the prevalence of activating KRAS mutations that increase mitogen-
activated protein kinase pathway signalling, TP53 tumor suppressor loss of function 
mutations and inactivating SMAD4 mutations that reduce transforming growth factor 
β (TGFβ)-induced changes in gene expression, all within a landscape of additional 
genetic variations. The most common pancreatic cancer is pancreatic ductal 
adenocarcinoma (PDAC), which develops from cells lining exocrine ducts that 
conduct digestive enzymes from acinar cells for delivery to the duodenum. 
Genetically-engineered mouse models of PDAC that closely recapitulate human 
PDAC development and progression have been established using oncogenic Kras 
selectively expressed in the pancreas, either alone (KC) or combined with mutated 
Trp53 (KPC) 4,5. 
PDAC is characterized by dense fibrous stroma composed of numerous cell 
types, including macrophages and α-smooth muscle actin (αSMA)-positive 
myofibroblasts, and deposition of extracellular matrix (ECM) material such as 
collagen1 and hyaluronic acid. In fact, transformed pancreatic epithelial cells are a 
minor constituent of PDAC tumors, with stromal components comprising the bulk of 
the tumor mass. The contribution of this desmoplastic reaction to pancreatic 
tumorigenesis is controversial, with evidence consistent with both contributory and 
inhibitory effects on tumorigenesis. In mouse models of PDAC, long-term inhibition 
or genetic deletions that limit the ability of pancreatic epithelial cells to respond to 
paracrine-acting tumor-secreted Hedgehog peptides, which enhance the tumor 
desmoplastic reaction 6, reduced stromal content and increased tumor aggression; 
while Hedgehog pathway activation in PDAC tumors with small molecule agonists 
increased stromal fibrosis and reduced epithelial cell proliferation 7,8. Furthermore, in 
another mouse model, depletion of αSMA-expressing myofibroblasts resulted in 
invasive, undifferentiated PDAC tumors with reduced survival 9. These observations 
suggested that the stromal component restrains PDAC. In addition, anti-stromal 
therapies for PDAC have not demonstrably improved patient survival or therapeutic 
responses in clinical trials 1. One possible explanation for the apparent restraining 
actions of the stromal component is that the “classical” mouse models are not 
adequate representations of the contribution of the stroma to PDAC. In particular, 
changes in protein expression levels might not reflect the influence that ECM protein 
organization and consequent mechanical properties of the tumor microenvironment 
have on PDAC growth and progression. 
Laklai et al. found in a number of human tumour samples that there were 
clear associations between poor PDAC differentiation, increased collagen fiber 
diameters and increased epithelial phosphorylated regulatory myosin light chain 
(pMLC2), consistent with functional links of tumor cell actomyosin tension and 
stromal remodelling with PDAC progression. Furthermore, patients with thicker 
collagen fibers adjacent to pancreatic lesions or increased epithelial pMLC2 had the 
shortest survival time, suggesting that altered ECM organization contributed to 
patient mortality. Reduced patient survival was also associated with relatively lower 
TGFβ signalling compared to longer surviving patients, and samples from patients 
with SMAD4 mutations had abundant collagen fibres, increased stiffness adjacent to 
pancreatic lesions and elevated pMLC2. Taken together, these results revealed 
significant links between reduced TGFβ signalling, ECM organization, tissue 
stiffness, epithelial cell actin-myosin tension and patient outcomes. 
TGFβ signalling proteins are frequently altered in human PDAC, with the 
cumulative frequency of SMAD4, SMAD3, TGFBR1, TGFBR2, ACVR1B or ACVR2A 
mutations being >50% 3. To determine how disruption of this pathway might 
contribute to PDAC, Laklai et al. 2 compared the fibrotic properties of tumors from KC 
or KPC mice with tumors from mice expressing oncogenic Kras plus pancreas-
selective deletion of one TGFβ receptor II (Tgfrb2) allele (KTC). Although expression 
of myofibroblast markers and total collagen levels were not different, collagen 
bundles were thicker in KTC tumors than in both KC and KPC tumors and 
associated with stiffer tissue. Accompanying these altered physical properties, KTC 
cells manifested several molecular responses typically mechanically induced, 
including nuclear accumulation of the YAP transcription factor, activated β1-integrin, 
phosphorylated active focal adhesion kinase (pFAK), and pMLC2. The KTC cells 
generated more actin-myosin mediated contractile force in vitro than the KPC and 
KC cells, which was dependent on the phosphorylation of MLC2 by the ROCK1 
protein kinase. When implanted into immunocompromised mice, KTC tumor cells 
induced ROCK1-dependent fibrosis, indicating that cell contractility leads to ECM 
protein remodelling, which in turn signals via mechanoresponsive pathways to 
increase cellular tension (Figure 1). 
Laklai et al. 2 next sought to identify signalling pathways altered by Tgfbr2 
deletion in PDAC. Tumor cells have been previously shown to signal via a cytokine 
induced G-protein coupled receptor (GPCR)-JAK-STAT pathway to induce 
actomyosin contractility, while ROCK-mediated contractility in tumor cells increases 
JAK-STAT signalling by inducing cytokine expression and secretion 10. KTC tumors 
had elevated levels of active phosphorylated Stat3 (pStat3) and increased collagen 
contracting ability indicating activation of the JAK-STAT pathway and KTC cell-
conditioned media increased KC tumor cell pStat3 levels and collagen contraction in 
vitro. In addition, JAK inhibitor treatment reduced collagen contraction by KTC cells, 
or by KC cells treated with KTC-conditioned medium. These results implicate 
elevated GPCR-JAK-STAT signalling in the increased actomyosin tension and matrix 
remodelling by PDAC cells with impaired TGFβ signalling. 
To determine whether mechanoresponsive signalling was sufficient to 
promote PDAC progression, the authors generated KC mice with pancreas-selective 
expression of V737N β1-integrin (KC/β1V737N) 11 to drive ligand-independent 
integrin clustering and focal adhesion signalling in the pancreas. The inclusion of 
active β1-integrin in KC mice was sufficient to recapitulate KTC phenotypes, 
including increased fibrosis, stromal stiffening, elevated pStat3, pFAK and pMLC2, 
and progression to PDAC. The effect of active β1-integrin was reversed by 
knockdown or inhibition of FAK, indicating that focal adhesion signalling was the key 
mediator of the effects of active β1-integrin. 
Similarly, KC mice expressing one allele of constitutively active Stat3 12 
(KC/Stat3C) were generated which resulted in elevated pFAK and pMLC2, increased 
fibrosis, stromal stiffening and reduced survival relative to control KC mice. In KTC 
mice lacking both alleles of Tgfrb2 and pancreas selective deletion of both copies of 
Stat3 there was complete reversal of the KTC phenotype and increased survival. 
Taken together, these experiments indicate that in PDAC reduced TGFβ 
signalling enables cell contractility that leads to ECM remodelling, increased 
microenvironmental stiffness and elevated JAK-STAT signalling. This signalling acts 
via mechanoresponsive pathways in a feed-forward loop to amplify cellular 
responses that promote PDAC growth and progression (Figure 1). The human 
relevance of these findings is supported by data from clinical samples indicating that 
PDAC patients with shorter survival times have elevated pStat3, pMLC2, nuclear 
Yap and increased collagen bundling, paralleled in PDAC patients with SMAD4 
mutations. 
There are several important implications of this study. Firstly, comparing total 
levels of collagen protein between tumors overlooks the importance of collagen fiber 
remodelling (such as bundling and cross-linking) in altering the stromal physical 
properties that may play significant roles in PDAC. As a result, methods that detect 
collagen organization, such as second harmonic generation microscopy, 
complement the information acquired from collagen staining alone. Secondly, the 
observation that certain PDAC genotypes, particularly with TGFβ signalling 
alterations, generate actomyosin contractile force to remodel ECM proteins and 
increase proximal stromal stiffness suggests that targeting both tumor and stromal 
cells to reduce the tumor-promoting influence of the microenvironment would likely 
be more efficacious than stromal cell targeting alone. The interactions between 
PDAC genotypes and tumor mechanical properties, highlighted in the study by Laklai 
et al. 2 in this issue of Nature Medicine, reinforces the importance of incorporating 
genetic context into future stromal-targeted therapy development.  
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Figure Legend 
Figure 1: Mechanosignaling of PDAC epithelial cells induces stromal 
remodeling 
Laklai, H., et al. indicate that PDAC tumors with decreased TGF signalling due to 
mutations in ligand receptors or SMAD4, increased JAK/Stat3 signalling or increased 
integrin clustering have elevated ROCK-dependent cell contractility. These tumors 
also secrete more matricellular proteins and cytokines, and have a remodelled and 
stiffer stromal extracellular matrix. In a feed-forward loop, the stiffer tumor 
microenvironment amplifies JAK/Stat3 and integrin-FAK-ROCK signalling to promote 
tumor aggressiveness. GPCR, G-protein coupled receptor; TGFBR, TGF receptor. 
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